Oleinik Alexandra, Romero Javier M, Schwab Kristin, Lev Michael H, Jhawar Nupur, Delgado Almandoz Josser E, Smith Eric E, Greenberg Steven M, Rosand Jonathan, Goldstein Joshua N
Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.
Stroke. 2009 Jul;40(7):2393-7. doi: 10.1161/STROKEAHA.108.546127. Epub 2009 May 21.
CT angiography (CTA) is receiving increased attention in intracerebral hemorrhage (ICH) for its role in ruling out vascular abnormalities and potentially predicting ongoing bleeding. Its use is limited by the concern for contrast induced nephropathy (CIN); however, the magnitude of this risk is not known.
We performed a retrospective analysis of a prospectively collected cohort of consecutive patients with ICH presenting to a single tertiary care hospital from 2002 to 2007. Demographic, clinical, and radiographic data were prospectively collected for all patients. Laboratory data and clinical course over the first 48 hours were retrospectively reviewed. Acute nephropathy was defined as any rise in creatinine of >25% or >0.5 mg/dL, such that the highest creatinine value was above 1.5 mg/dL.
539 patients presented during the study period and had at least 2 creatinine measurements. 348 (65%) received a CTA. Acute nephropathy developed in 6% of patients who received a CTA and in 10% of those who did not (P=0.1). Risk of nephropathy was 14% in those receiving no contrast (130 patients), 5% in those receiving 1 contrast study (124 patients), and 6% in those receiving >1 contrast study (244 patients). Neither CTA nor any use of contrast predicted nephropathy in univariate or multivariate analysis.
The risk of acute nephropathy after ICH was not increased by use of CTA. Studies of CIN that do not include a control group may overestimate the influence of contrast. Patients with ICH appear to have an 8% risk of developing "Hospital-Acquired Nephropathy."
CT血管造影(CTA)在脑出血(ICH)中因在排除血管异常及潜在预测持续出血方面的作用而受到越来越多的关注。其应用受到对比剂肾病(CIN)的担忧限制;然而,这种风险的程度尚不清楚。
我们对2002年至2007年在一家三级医疗中心就诊的连续ICH患者的前瞻性队列进行了回顾性分析。前瞻性收集了所有患者的人口统计学、临床和影像学数据。回顾性分析了最初48小时内的实验室数据和临床病程。急性肾病定义为肌酐升高>25%或>0.5mg/dL,且最高肌酐值高于1.5mg/dL。
在研究期间有539例患者就诊且至少进行了2次肌酐测量。348例(65%)接受了CTA检查。接受CTA检查的患者中有6%发生急性肾病,未接受CTA检查的患者中有10%发生急性肾病(P=0.1)。未接受对比剂的患者(130例)肾病风险为14%,接受1次对比剂检查的患者(124例)为5%,接受>1次对比剂检查的患者(244例)为6%。在单因素或多因素分析中,CTA及任何对比剂的使用均未预测肾病。
ICH后使用CTA并未增加急性肾病的风险。未设对照组的CIN研究可能高估了对比剂的影响。ICH患者发生“医院获得性肾病”的风险似乎为8%。